Evidence map›Paper›PMID 38849448›Full record

ArticleNPJ precision oncology2024

Integration of pre-treatment computational radiomics, deep radiomics, and transcriptomics enhances soft-tissue sarcoma patient prognosis.

Amandine Crombé, Carlo Lucchesi, Frédéric Bertolo, Michèle Kind, Mariella Spalato-Ceruso, Maud Toulmonde, Vanessa Chaire, Audrey Michot, Jean-Michel Coindre, Raul Perret and 3 more

Abstract read
In one paragraph

Article in NPJ precision oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. MRI features outperform histologic grade for outcome prediction in translocation-driven enriched soft-tissue sarcoma.Cancer imaging : the official publication of the International Cancer Imaging Society · 2026
    Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Amandine Crombé *Department of Oncologic Imaging, Bergonié Institute, F-33076, Bordeaux, France. amandine.crombe@chu-bordeaux.fr.ORCID http://orcid.org/0000-0003-0098-6482
Carlo Lucchesi *Department of Bioinformatics, Bergonié Institute, F-33076, Bordeaux, France.ORCID http://orcid.org/0000-0001-6657-2341
Frédéric BertoloDepartment of Bioinformatics, Bergonié Institute, F-33076, Bordeaux, France.
Michèle KindDepartment of Oncologic Imaging, Bergonié Institute, F-33076, Bordeaux, France.
Mariella Spalato-CerusoBordeaux Institute of Oncology, BRIC U1312, Sarcotarget team, INSERM, University of Bordeaux, Institut Bergonié, F-33000, Bordeaux, France.ORCID http://orcid.org/0000-0002-7582-3365
Maud ToulmondeBordeaux Institute of Oncology, BRIC U1312, Sarcotarget team, INSERM, University of Bordeaux, Institut Bergonié, F-33000, Bordeaux, France.
Vanessa ChaireBordeaux Institute of Oncology, BRIC U1312, Sarcotarget team, INSERM, University of Bordeaux, Institut Bergonié, F-33000, Bordeaux, France.
Audrey MichotBordeaux Institute of Oncology, BRIC U1312, Sarcotarget team, INSERM, University of Bordeaux, Institut Bergonié, F-33000, Bordeaux, France.
Jean-Michel CoindreBordeaux Institute of Oncology, BRIC U1312, Sarcotarget team, INSERM, University of Bordeaux, Institut Bergonié, F-33000, Bordeaux, France.
Raul PerretDepartment of Pathology, Bergonié Institute, F-33076, Bordeaux, France.ORCID http://orcid.org/0000-0003-2698-0249
François Le LoarerBordeaux Institute of Oncology, BRIC U1312, Sarcotarget team, INSERM, University of Bordeaux, Institut Bergonié, F-33000, Bordeaux, France.
Aurélien BourdonDepartment of Bioinformatics, Bergonié Institute, F-33076, Bordeaux, France.
Antoine ItalianoBordeaux Institute of Oncology, BRIC U1312, Sarcotarget team, INSERM, University of Bordeaux, Institut Bergonié, F-33000, Bordeaux, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Our objective was to capture subgroups of soft-tissue sarcoma (STS) using handcraft and deep radiomics approaches to understand their relationship with histopathology, gene-expression profiles, and metastatic relapse-free survival (MFS). We included all consecutive adults with newly diagnosed locally advanced STS (N = 225, 120 men, median age: 62 years) managed at our sarcoma reference center between 2008 and 2020, with contrast-enhanced baseline MRI. After MRI postprocessing, segmentation, and reproducibility assessment, 175 handcrafted radiomics features (h-RFs) were calculated. Convolutional autoencoder neural network (CAE) and half-supervised CAE (HSCAE) were trained in repeated cross-validation on representative contrast-enhanced slices to extract 1024 deep radiomics features (d-RFs). Gene-expression levels were calculated following RNA sequencing (RNAseq) of 110 untreated samples from the same cohort. Unsupervised classifications based on h-RFs, CAE, HSCAE, and RNAseq were built. The h-RFs, CAE, and HSCAE grouping were not associated with the transcriptomics groups but with prognostic radiological features known to correlate with lower survivals and higher grade and SARCULATOR groups (a validated prognostic clinical-histological nomogram). HSCAE and h-RF groups were also associated with MFS in multivariable Cox regressions. Combining HSCAE and transcriptomics groups significantly improved the prognostic performances compared to each group alone, according to the concordance index. The combined radiomic-transcriptomic group with worse MFS was characterized by the up-regulation of 707 genes and 292 genesets related to inflammation, hypoxia, apoptosis, and cell differentiation. Overall, subgroups of STS identified on pre-treatment MRI using handcrafted and deep radiomics were associated with meaningful clinical, histological, and radiological characteristics, and could strengthen the prognostic value of transcriptomics signatures.

Identifiers

PMID38849448
PMCPMC11161510

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.